Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Kyverna Therapeutics, Inc. ( (KYTX) ) has provided an update.
On December 15, 2025, Kyverna Therapeutics announced positive topline data from its Phase 2 trial of mivocabtagene autoleucel (miv-cel) for treating stiff person syndrome (SPS). The trial demonstrated significant clinical benefits, including reversing disability and eliminating the need for immunotherapies after a single dose, with no high-grade adverse effects observed. These results could position miv-cel as the first FDA-approved CAR T-cell therapy for autoimmune diseases, marking a potential breakthrough for SPS patients.
The most recent analyst rating on (KYTX) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Kyverna Therapeutics, Inc. stock, see the KYTX Stock Forecast page.
Spark’s Take on KYTX Stock
According to Spark, TipRanks’ AI Analyst, KYTX is a Underperform.
Kyverna Therapeutics, Inc. faces significant financial challenges, with consistent losses and zero revenue. The company’s technical indicators and valuation metrics reflect ongoing operational and financial difficulties. Key risks include negative profitability and weak market momentum, which significantly impact the stock’s performance.
To see Spark’s full report on KYTX stock, click here.
More about Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases.
Average Trading Volume: 708,589
Technical Sentiment Signal: Buy
Current Market Cap: $384.5M
For an in-depth examination of KYTX stock, go to TipRanks’ Overview page.